farmaecFARMAKOEKONOMIKA. Modern Pharmacoeconomics and PharmacoepidemiologyФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология2070-49092070-4933IRBIS LLC10.17749/2070-4909.2019.12.4.333-341farmaec-316Research ArticleINTERNATIONAL PRACTICESЗАРУБЕЖНЫЙ ОПЫТThe health technology assessment system in AustraliaОценка технологий здравоохранения в Австралииhttps://orcid.org/0000-0003-1581-0703ОмельяновскийВ. В.OmelyanovskiyV. V.

Омельяновский Виталий Владимирович – д. м. н., профессор, руководитель Центра финансов здравоохранения НИФИ Минфина России, директор лаборатории оценки технологий здравоохранения Института прикладных экономических исследований РАНХиГС при Президенте РФ.

Researcher ID: P-6911-2018Scopus Author ID: 6507287753

Настасьинский пер., д. 3 стр. 2, Москва 127006

просп. Вернадского, д. 82, Москва 119571

Vitaly V. Omelyanovskiy – MD, PhD, Professor, Head of the Center for Healthcare Funding, Financial Research Institute of the Ministry of Finance of Russia; Head of the Laboratory for Health Technology Assessment at the Institute of Applied Economic Research, Russian Presidential Academy of National Economy and Public Administration (RANEPA).

Researcher ID: P-6911-2018Scopus Author ID: 6507287753

3-2 Nastasyinsky pereulok, Moscow 127006

82 Vernadskogo prospect, Moscow 119571

https://orcid.org/0000-0002-4358-0290СайбельЕ. С.SaybelE. S.

Сайбель Егор Сергеевич - к. фарм. н. ведущий специалист отдела методологического обеспечения проведения комплексной оценки технологий в здравоохранении.

Хохловский пер., вл. 10 стр. 5, Москва 109028

Yegor S. Saybel – PhD, Lead Specialist, Center for Healthcare Quality Assessment and Control, Ministry of Health of the Russian Federation.

10-5 Khokhlovskii pereulok, Moscow 109028

saybel@rosmedex.ruhttps://orcid.org/0000-0003-4839-8081БезденежныхТ. П.BezdenezhnykhT. P.

Безденежных Татьяна Павловна – ведущий специалист отдела методологического обеспечения проведения комплексной оценки технологий в здравоохранении ФГБУ «ЦЭККМП» Минздрава России; младший научный сотрудник Центра финансов здравоохранения НИФИ Минфина России.

Настасьинский пер., д. 3 стр. 2, Москва 127006

Хохловский пер., вл. 10 стр. 5, Москва 109028

Tatiana P. Bezdenezhnykh – Lead Specialist, Center for Healthcare Quality Assessment and Control, Ministry of Health of the Russian Federation; Junior Researcher at the Center for Healthcare Funding, Financial Research Institute of the Ministry of Finance of Russia.

3-2 Nastasyinsky pereulok, Moscow 127006

10-5 Khokhlovskii pereulok, Moscow 109028

https://orcid.org/0000-0002-7340-2698ХачатрянГ. Р.KhachatryanG. R.

Хачатрян Георгий Рубенович – начальник отдела методологического обеспечения проведения комплексной оценки технологий в здравоохранении ФГБУ «ЦЭККМП» Минздрава России; младший научный сотрудник Центра финансов здравоохранения НИФИ Минфина России.

Настасьинский пер., д. 3 стр. 2, Москва 127006

Хохловский пер., вл. 10 стр. 5, Москва 109028

Georgii R. Khachatryan – Head of the Department of Methodological Support of Comprehensive Health Technology Assessment, Center for Healthcare Quality Assessment and Control, Ministry of Health of the Russian Federation; Junior Researcher at the Center for Healthcare Funding, Financial Research Institute of the Ministry of Finance of Russia.

3-2 Nastasyinsky pereulok, Moscow 127006

10-5 Khokhlovskii pereulok, Moscow 109028

Федеральное государственное бюджетное учреждение «Научно-исследовательский финансовый институт Министерства финансов Российской Федерации»; Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования «Российская академия народного хозяйства и государственной службы при Президенте Российской Федерации»РоссияFinancial Research Institute of the Ministry of Finance of the Russian Federation; Russian Presidential Academy of National Economy and Public AdministrationRussian FederationФедеральное государственное бюджетное учреждение «Центр экспертизы и контроля качества медицинской помощи» Министерства здравоохранения Российской ФедерацииРоссияCenter for Healthcare Quality Assessment and Control of the Ministry of Healthcare of the Russian FederationRussian FederationФедеральное государственное бюджетное учреждение «Научно-исследовательский финансовый институт Министерства финансов Российской Федерации»; Федеральное государственное бюджетное учреждение «Центр экспертизы и контроля качества медицинской помощи» Министерства здравоохранения Российской ФедерацииРоссияFinancial Research Institute of the Ministry of Finance of the Russian Federation; Center for Healthcare Quality Assessment and Control of the Ministry of Healthcare of the Russian FederationRussian Federation201918022020124333341Copyright © Omelyanovskiy V.V., Saybel E.S., Bezdenezhnykh T.P., Khachatryan G.R., 20202020Омельяновский В.В., Сайбель Е.С., Безденежных Т.П., Хачатрян Г.Р.Omelyanovskiy V.V., Saybel E.S., Bezdenezhnykh T.P., Khachatryan G.R.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacoeconomics.ru/jour/article/view/316

In Australia, the federal government is in charge of providing the health care to patients. The government agencies determine the list of reimbursable pharmaceuticals and medical services and also define the preferential categories of the population. The states and territories may have their own health care programs in addition to the federal ones. The Pharmaceutical Benefits Advisory Committee (PBAC) is responsible for the health technology assessment (HTA) and decides which technology is eligible for reimbursement by the federal budget. The drug evaluation process includes five stages: a review of general information about the product, assessment of its clinical efficacy, cost-effectiveness analysis, assessment of financial implications of including the drug in the reimbursement list, and consideration of any other factors that may influence the committee decision. In addition to the full reimbursement of pharmaceuticals, the committee may decide to provide funding based on a managed entry agreement.

Главные направления деятельности системы здравоохранения Австралии координируются федеральным правительством, которое определяет перечни возмещаемых препаратов и медицинских услуг, а также устанавливает льготные категории населения. Штаты и территории могут иметь собственные медицинские программы в дополнение к федеральным. Консультативный Комитет по фармацевтическим льготам (англ. – Pharmaceutical Benefits Advisory Committee, PBAC), отвечающий за оценку технологий здравоохранения (ОТЗ), принимает решение о целесообразности государственного возмещения препарата. Рекомендации PBAC играют решающую роль при принятии министром здравоохранения решения о возмещении. Процесс оценки лекарственных препаратов состоит из пяти этапов: обзор общих сведений о препарате, оценка клинической эффективности, оценка экономической эффективности, оценка финансовых последствий включения препарата в возмещаемые списки и обзор дополнительных факторов, которые могут повлиять на решения комитета. Помимо полного возмещения стоимости применения препарата для популяции пациентов Австралии, комитет может вынести решение о предоставлении финансирования на основе соглашений об организации доступа пациентов к ЛП.

оценка технологий здравоохранениявозмещениесистема здравоохранения Австралиилекарственное обеспечениеhealth technology assessmentreimbursementAustralian healthcaredrug provisionReferencesОфициальный сайт Правительства Австралии. [Электронный ресурс] URL: https://www.australia.gov.au/about-government/how-government-works/federation. https://www.australia.gov.au/about-government/how-government-works/federation Дата обращения: 09.10.2019.Official website of the Australian Government. [Electronic resource] URL: https://www.australia.gov.au/about-government/how-government-works/federation. Accessed: 09.10.2019.Mirror, Mirror 2017: International Comparison Reflects Flaws and Opportunities for Better U.S. Health Care. July 13, 2017. By: Eric C. Schneider, M.D.: Dana O. Sarnak: David Squires: Arnav Shah: Michelle M. Doty. [Электронный ресурс] URL: https://interactives.commonwealthfund.org/2017/july/mirror-mirror/. Дата обращения: 09.10.2019.Mirror, Mirror 2017: International Comparison Reflects Flaws and Opportunities for Better U.S. Health Care. July 13, 2017. By: Eric C. Schneider, M.D.: Dana O. Sarnak: David Squires: Arnav Shah: Michelle M. Doty. [Electronic resource] URL: https://interactives.commonwealthfund.org/2017/july/mirror-mirror/. Accessed: 09.10.2019.Australian Government Australian Institute of Health and Welfare. [Электронный ресурс] URL: https://www.aihw.gov.au/reports/healthwelfare-expenditure/health-expenditure-australia-2016-17/contents/summary. Дата обращения: 09.10.2019.Australian Government Australian Institute of Health and Welfare. [Electronic resource] URL: https://www.aihw.gov.au/reports/health-welfare-expenditure/health-expenditure-australia-2016-17/contents/summary. Accessed: 09.10.2019.Mossialos E. et al. International profiles of health care systems. 2015. The Commonwealth Fund, January 2016. [Электронный ресурс] URL: https://international.commonwealthfund.org/countries/australia/. Дата обращения: 09.10.2019.Mossialos E. et al. International profiles of health care systems. 2015. The Commonwealth Fund, January 2016. [Electronic resource] URL: https://international.commonwealthfund.org/countries/australia/. Accessed: 09.10.2019.Expenditure and Prescriptions Twelve Months to 30 June 2017. PBS Information Management Section Pricing and Policy Branch Technology Assessment and Access Division. [Электронный ресурс] URL: http://www.pbs.gov.au/statistics/expenditureprescriptions/2016-2017/expenditure-and-prescriptions-twelvemonths-to-30-june-2017.pdf. Дата обращения: 09.10.2019.Expenditure and Prescriptions Twelve Months to 30 June 2017. PBS Information Management Section Pricing and Policy Branch Technology Assessment and Access Division. [Electronic resource] URL: http://www.pbs.gov.au/statistics/expenditure-prescriptions/2016-2017/expenditure-and-prescriptions-twelve-months-to-30-june-2017.pdf. Accessed: 09.10.2019.Официальный сайт Министерства Здравоохранения Австралии. [Электронный ресурс] URL: https://beta.health.gov.au/about-us/the-australian-health-system. Дата обращения: 09.10.2019.Official website of the Australian Department of Health. [Electronic resource] URL: https://beta.health.gov.au/about-us/the-australian-health-system Accessed: 09.10.2019.Официальный сайт Австралийского Налогового Управления. [Электронный ресурс] URL: https://www.ato.gov.au/Individuals/Medicare-levy/. Дата обращения: 09.10.2019.Official site of the Australian Tax Administration. [Electronic resource] URL: https://www.ato.gov.au/Individuals/Medicare-levy/. Accessed: 09.10.2019.Официальный сайт Омбудсмена по делам частного страхования. [Электронный ресурс] URL: https://www.privatehealth.gov.au/health_insurance/howitworks/index.htm. Дата обращения: 09.10.2019.Official website of the Ombudsman for Private Insurance. [Electronic resource] URL: https://www.privatehealth.gov.au/health_insurance/howitworks/index.htm. Accessed: 09.10.2019.О Программе льготного лекарственного обеспечения. [Электронный ресурс] URL: http://www.pbs.gov.au/info/about-thepbs#What_is_the_RPBS. Дата обращения: 09.10.2019.About the program of preferential drug provision. [Electronic resource] URL: http://www.pbs.gov.au/info/about-the-pbs#What_is_ the_RPBS. Accessed: 09.10.2019.Ежегодный отчет Министерства Здравоохранения Австралии. [Электронный ресурс] URL: https://beta.health.gov.au/resources/publications/department-of-health-annual-report-2017-18. Дата обращения: 09.10.2019.Australian Department of Health Annual Report. [Electronic resource] URL: https://beta.health.gov.au/resources/publications/department-of-health-annual-report-2017-18. Accessed: 09.10.2019.Официальный сайт Австралийской администрации лекарственных средств. [Электронный ресурс] URL: https://www.tga.gov.au/sme-assist/overview-applying-market-authorisation. Дата обращения: 09.10.2019.Australian Medicines Administration Official Website. [Electronic resource] URL: https://www.tga.gov.au/sme-assist/overview-applying-market-authorisation. Accessed: 09.10.2019.Procedure guidance for listing medicines on the Pharmaceutical Benefits Scheme (including consideration of vaccines for the National Immunisation Program). Australian Government Department of Health. Version 1.3. September 2018.Procedure guidance for listing medicines on the Pharmaceutical Benefits Scheme (including consideration of vaccines for the National Immunisation Program). Australian Government Department of Health. Version 1.3. September 2018.Senate Community Affairs Reference Committee. Availability of new, innovative and specialist cancer drugs in Australia. Final Report. September. 2015.Senate Community Affairs Reference Committee. Availability of new, innovative and specialist cancer drugs in Australia. Final Report. September. 2015.Консультативный комитет по фармацевтическим льготам Австралии. [Электронный ресурс] URL: https://www.pbs.gov.au/pbs/industry/listing/participants/pbac. Дата обращения: 09.10.2019.The Pharmaceutical Benefits Advisory Committee of Australia. [Electronic resource] URL: https://www.pbs.gov.au/pbs/industry/listing/participants/pbac. Accessed: 09.10.2019.Australian Government. Department of Health. The Pharmaceutical Benefits Scheme. Procedure guidance for listing medicines. [Электронный ресурс] URL: http://www.pbs.gov.au/industry/listing/procedureguidance/files/Procedure-Guidance-Listing-Medicines-on-the-PBS-v1-6.pdf. Дата обращения: 09.10.2019.Australian Government. Department of Health. The Pharmaceutical Benefits Scheme. Procedure guidance for listing medicines. [Electronic resource] URL: http://www.pbs.gov.au/industry/listing/procedure-guidance/files/Procedure-Guidance-Listing-Medicines-on-the-PBS-v1-6.pdf. Accessed: 09.10.2019.Henry D.A., Hill S.R. & Harris A. Drug Prices and Value for Money. JAMA: The Journal of the American Medical Association. 2005; 294: 2630-2632.Henry D.A., Hill S.R. & Harris A. Drug Prices and Value for Money. JAMA: The Journal of the American Medical Association. 2005; 294: 2630-2632.George B., Harris A. & Mitchell A. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics. 2001; 19: 1103-9.George B., Harris A. & Mitchell A. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics. 2001; 19: 1103-9.Harris A. H., Hill S. R., Chin G., Li J. J. & Walkom E. The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004. Medical Decision Making. 2008; 28: 713-22.Harris A. H., Hill S. R., Chin G., Li J. J. & Walkom E. The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004. Medical Decision Making. 2008; 28: 713-22.Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee Version 5.0 September 2016. [Электронный ресурс] URL: https://pbac.pbs.gov.au/content/information/files/pbac-guidelines-version-5.pdf. Дата обращения: 09.10.2019.Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee Version 5.0 September 2016. [Electronic resource] URL: https://pbac.pbs.gov.au/content/information/files/pbac-guidelines-version-5.pdf. Accessed: 09.10.2019.Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee Section 1. [Электронный ресурс] URL: https://pbac.pbs.gov.au/section-1-context.html. Дата обращения: 09.10.2019.Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee Section 1. [Electronic resource] URL: https://pbac.pbs.gov.au/section-1-context.html. Accessed: 09.10.2019.Robinson M. F. et al. Characteristics of managed entry agreements in Australia. International journal of technology assessment in health care. 2018; 34 (1): 46-55.Robinson M. F. et al. Characteristics of managed entry agreements in Australia. International journal of technology assessment in health care. 2018; 34 (1): 46-55.Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee Section 2. [Электронный ресурс] URL: https://pbac.pbs.gov.au/section2-clinical-evaluation.html. Дата обращения: 09.10.2019.Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee Section 2. [Electronic resource] URL: https://pbac.pbs.gov.au/section2-clinical-evaluation.html. Accessed: 09.10.2019.Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee Section 3. [Электронный ресурс] URL: https://pbac.pbs.gov.au/section-3-economic-evaluation.html. Дата обращения: 09.10.2019.Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee Section 3. [Electronic resource] URL: https://pbac.pbs.gov.au/section-3-economic-evaluation.html. Accessed: 09.10.2019.Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee Section 4. [Электронный ресурс] URL: https://pbac.pbs.gov.au/section-4-use-of-the-medicine-in-practice. html. Дата обращения: 09.10.2019.Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee Section 4. [Electronic resource] URL: https:// pbac.pbs.gov.au/section-4-use-of-the-medicine-in-practice.html. Accessed: 09.10.2019Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee Section 5. [Электронный ресурс] URL:https://pbac.pbs.gov.au/section-5-options-to-present-additionalrelevant-information.html. Дата обращения: 09.10.2019.Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee Section 5. [Electronic resource] URL: https://pbac.pbs.gov.au/section-5-options-to-present-additional-relevant-information.html. Accessed: 09.10.2019.Australian Government. Department of Health. 7.1 Notification of outcomes of PBAC. [Электронный ресурс] URL: http://www.pbs.gov.au/info/industry/listing/procedure-guidance/7-post-pbac-decisionprocedures-sponsors/7-1-notification-of-outcomes-of-pbac. Дата обращения: 09.10.2019.Australian Government. Department of Health. 7.1 Notification of outcomes of PBAC. [Electronic resource] URL: http://www.pbs.gov.au/info/industry/listing/procedure-guidance/7-post-pbac-decision-procedures-sponsors/7-1-notification-of-outcomes-of-pbac. Accessed: 09.10.2019.PBS Calendars. [Электронный ресурс] URL: http://www.pbs.gov.au/info/industry/useful-resources/pbs-calendar. Дата обращения: 09.10.2019.PBS Calendars. [Electronic resource] URL: http://www.pbs.gov.au/info/industry/useful-resources/pbs-calendar. Accessed: 09.10.2019.Paris V., Belloni A. Value in pharmaceutical pricing country profile: Australia. OECD Health Working Papers. 2014. №63.Paris V., Belloni A. Value in pharmaceutical pricing country profile: Australia. OECD Health Working Papers. 2014. №63.Formulary Allocations. Australian Government. Department of Health. [Электронный ресурс] URL: http://www.pbs.gov.au/info/industry/pricing/pbs-items/formulary-allocations. Дата обращения: 09.10.2019.Formulary Allocations. Australian Government. Department of Health. [Electronic resource] URL: http://www.pbs.gov.au/info/industry/pricing/pbs-items/formulary-allocations. Accessed: 09.10.2019.Pharmaceutical Benefits Scheme Post-market Reviews Information for Stakeholders. [Электронный ресурс] URL: http://www.pbs.gov.au/reviews/subsidised-medicines-reviews-files/post-marketreview-framework-10-2014.pdf. Дата обращения: 09.10.2019.Pharmaceutical Benefits Scheme Post-market Reviews Information for Stakeholders. [Electronic resource] URL: http://www.pbs.gov.au/reviews/subsidised-medicines-reviews-files/post-market-review-framework-10-2014.pdf. Accessed: 09.10.2019.

The authors declare that there are no conflicts of interest present.